Hibercell and biodesix initiate broad collaboration for companion diagnostic discovery, development and commercialization

New york & boulder, colo.--(business wire)--biodesix, inc. (nasdaq: bdsx) today announced an agreement with hibercell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis, to further the development of an enzyme-linked immunosorbent assay (elisa) as a companion diagnostic in future registrational trials in breast cancer for imprime pgg programs. terms of the partnership were not disclosed. biodesix leverages multiple technologies with its proprietary artifici
BDSX Ratings Summary
BDSX Quant Ranking